A case of organizing pneumonia (OP) associated with pembrolizumab

Drug Target Insights

Volumn 10, Issue , 2016, Pages 9-12

  Fragkou, Paraskevi ^a   Souli, Maria ^a   Theochari, Maria ^a   Kontopoulou, Christina ^a   Loukides, Stelios ^a   Koumarianou, Anna ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Melanoma; OP; Organizing pneumonia; Pembrolizumab; Side effect

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; CEFTRIAXONE; DACARBAZINE; IPILIMUMAB; LEVOFLOXACIN; PEMBROLIZUMAB; PREDNISOLONE; ZOLEDRONIC ACID;

ABNORMAL RESPIRATORY SOUND; ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CASE REPORT; COUGHING; CYTODIAGNOSIS; DEATH; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG WITHDRAWAL; DRY COUGH; DYSPNEA; FEMALE; FIBEROPTIC BRONCHOSCOPY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LABORATORY TEST; LIVER METASTASIS; LOWER RESPIRATORY TRACT INFECTION; LUNG INFILTRATE; LUNG LAVAGE; LYMPH NODE METASTASIS; METASTATIC MELANOMA; MIDDLE AGED; MUCOSAL MELANOMA; MULTIPLE CYCLE TREATMENT; NOSE CANCER; NOSE CAVITY; ORGANIZING PNEUMONIA; THORAX RADIOGRAPHY;

EID: 84976333320     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.S31565     Document Type: Article

References (19)

1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-1982.
2. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Bethesda, MD: NIH. Published: May 28, 2009 (v4.03: June 14, 2010). NIH Publication No. 09-5410. Revised June 2010.
3. McDermott D, Lebbe C, Hodi FS, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40:1056-1064.
4. Eggermont AM, Maio M, Robert C. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Semin Oncol. 2015;42:429-435.
5. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
6. Thibult ML, Mamessier E, Gertner-Dardenne J, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25:129-137.
7. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17-37.
8. Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A. 2009;106:6303-6308.
9. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One. 2015;10:e0131403.
10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
11. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115-123.
12. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144.
13. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-748.
14. Barker AF, Bergeron A, Rom WN, et al. Obliterative bronchiolitis. N Engl J Med. 2014;370:1820-1828.
15. Cordier JF. Cryptogenic organising pneumonia. Eur Respir J. 2006;28:422-446.
16. Nishimura K, Itoh H. High-resolution computed tomographic features of bronchiolitis obliterans organizing pneumonia. Chest. 1992;102:26S-31S.
17. Kim KM, Kim HC, Jeon KN, et al. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J. 2008;49:155-158.
18. Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373:288-290.
19. Nakashima K, Naito T, Omori S, et al. Organizing pneumonia induced by nivolumab in a patient with metastatic melanoma. J Thorac Oncol. 2016;11(3): 432-433.